Domestic pharmaceuticals enter a new stage, the Sci-Tech Innovation Pharmaceutical ETF Huaxia(588130) closes up 1.19%

As of the market close on April 2, 2026, the STAR Market Biopharmaceutical Index (000683) on the Shanghai Stock Exchange rose 0.78%. Among constituent stocks, San Sheng Guo Jian rose 13.41%, Huiyu Pharmaceutical rose 10.77%, BoRui Medicine rose 6.77%, YiFang Bio rose 5.98%, and YuanDong Bio rose 5.62%. The Huaxia STAR Market Biopharmaceutical ETF (588130) rose 1.19%, with the latest price at 1.11 yuan.

In the news, the European Lung Cancer Conference (ELCC) 2026 was held in Copenhagen from March 25 to 28, with multiple research results in the lung cancer field by domestic innovative drug companies making a concentrated appearance: 7 studies were released including Innovent’s aderebeli monoclonal antibody and Apatinib mesylate; TQB2922 dual-antibody Phase I data from Simcere Tianjin Tiansheng were selected for an oral presentation; the OS analysis of Kelun-Biotech’s alconsa-tuzumab OS was announced in the form of a major oral presentation as LBA4; for Incyte’s ilruetinitenib (Irexitnib) Phase III OS long-term follow-up data were disclosed for the first time; and the Phase III clinical results of Junshi Biosciences’ toripalimab subcutaneous formulation were for the first domestically developed PD-1 subcutaneous Phase III study. The intensive readouts of clinical data confirm that domestic innovative drugs are accelerating their shift from following to leading.

According to Galaxy Securities, the pharmaceutical and biological industry is undergoing a transition from “a combination of imitation and innovation” to “original innovation and high-quality development.” The “14th Five-Year Plan” first listed biopharmaceuticals as a national “emerging pillar industry,” further elevating its strategic positioning. The country strongly supports this transition through policies across the entire value chain, accelerating the shift from a “major pharmaceutical country” to a “pharmaceutical power.”

In terms of liquidity, the Huaxia STAR Market Biopharmaceutical ETF saw a turnover rate of 13.05% during intraday trading, with trading volume of 8.0998 million yuan; market activity was active. Looking at a longer timeframe, as of April 2, the ETF’s average daily trading volume over the past week was 11.8145 million yuan.

The data show that as of March 31, 2026, the top ten weight stocks of the STAR Market Biopharmaceutical Index (000683) on the Shanghai Stock Exchange are United Imaging Healthcare, BeiGene, Akilli, BaiLi Pharmatech, Rongchang Biotech, Witty Medical, Junshi Biosciences, Zeyen Pharmaceutical, BoRui Medicine, and iRui Tech. The combined share of the top ten weight stocks is 48.91%.